Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADU-S100 and Pembrolizumab in Head and Neck Cancer
NCT03937141Phase 2Terminated
- Sponsor
- Chinook Therapeutics
- Start
- Aug 2019
- Primary completion
- May 2021
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of ADU-S100 in head and neck squamous cell carcinoma (HNSCC), sponsored by Chinook Therapeutics. Started Aug 2019; status: terminated.
02
Drugs
ADU-S100
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03937141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03937141.